The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage
Abstract
The SIBLING family (small integrin-binding ligand N-linked glycoproteins) of mineral-regulating proteins, which includes matrix extracellular phosphoglycoprotein (MEPE) and osteopontin (OPN), contains an acidic serine- and aspartate-rich motif (ASARM). X-linked hypophosphatemia caused by inactivating mutations of the PHEX gene results in elevated mineralization-inhibiting MEPE-derived ASARM peptides. Although the OPN ASARM motif shares 60% homology with MEPE ASARM, it is still unknown whether OPN ASARM similarly inhibits mineralization. In this study we have examined the role of OPN ASARM and its interaction with PHEX enzyme using an osteoblast cell culture model, mass spectrometry, mineral-binding assays, and computational modeling. MC3T3-E1 osteoblast cultures were treated with differently phosphorylated OPN ASARM peptides [with 5 phosphoserines (OpnAs5) or 3 phosphoserines (OpnAs3)] or with control nonphosphorylated peptide (OpnAs0). Phosphorylated peptides dose-dependently inhibited mineralization, and binding of phosphorylated peptides to mineral was confirmed by a hydroxyapatite-binding assay. OpnAs0 showed no binding to hydroxyapatite and did not inhibit culture mineralization. Computational modeling of peptide-mineral interactions indicated a favorable change in binding energy with increasing phosphorylation consistent with hydroxyapatite-binding experiments and inhibition of culture mineralization. Addition of PHEX rescued inhibition of mineralization by OpnAs3. Mass spectrometry of cleaved peptides after ASARM-PHEX incubations identified OpnAs3 as a PHEX substrate. We conclude that OPN ASARM inhibits mineralization by binding to hydroxyapatite in a phosphorylation-dependent manner and that this inhibitor can be cleaved by PHEX, thus providing a mechanistic explanation for how loss of PHEX activity in X-linked hyposphosphatemia can lead to extracellular matrix accumulation of ASARM resulting in the osteomalacia. © 2010 American Society for Bone and Mineral Research
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteopontin Deficiency Increases Mineral Content and Mineral Crystallinity in Mouse Bone
Boskey, A. L., Spevak, L., Paschalis, E., Doty, S. B., & McKee, M. D. (2002) · Calcified Tissue International · doi:10.1007/s00223-001-1121-z · Cited by 332
Self-citationAddison, W. N., Nakano, Y., Loisel, T., Crine, P., & McKee, M. D. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080601 · Cited by 214
Self-citation
Research works printed but not linked: 48
- Boskey, 2003, Biomineralization: an overview, Connect Tissue Res., 44, 5, 10.1080/03008200390152007 · DOI · Paper page
- Sodek, 2000, Osteopontin, Crit Rev Oral Biol Med., 11, 279, 10.1177/10454411000110030101 · DOI · Paper page
- Giachelli, 2005, Inducers and inhibitors of biomineralization: lessons from pathological calcification, Orthod Craniofac Res., 8, 229, 10.1111/j.1601-6343.2005.00345.x · DOI
- Denhardt, 1993, Osteopontin: a protein with diverse functions, FASEB J., 7, 1475, 10.1096/fasebj.7.15.8262332 · DOI · Paper page
- Christensen, 2005, Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications, Biochem J., 390, 285, 10.1042/BJ20050341 · DOI · Paper page
- Keykhosravani, 2005, Comprehensive identification of post-translational modifications of rat bone osteopontin by mass spectrometry, Biochemistry., 44, 6990, 10.1021/bi050109p · DOI
- Christensen, 2007, Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties, J Biol Chem., 282, 19463, 10.1074/jbc.M703055200 · DOI
- Gericke, 2005, Importance of phosphorylation for osteopontin regulation of biomineralization, Calcif Tissue Int., 77, 45, 10.1007/s00223-004-1288-1 · DOI · Paper page
- Kazanecki, 2007, Control of osteopontin signaling and function by post-translational phosphorylation and protein folding, J Cell Biochem., 102, 912, 10.1002/jcb.21558 · DOI · Paper page
- Agnihotri, 2001, Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin), J. Biol. Chem., 276, 28261, 10.1074/jbc.M103608200 · DOI · Paper page
- Dean, 2007, Proteomics Discovery of Metalloproteinase Substrates in the Cellular Context by iTRAQTM Labeling Reveals a Diverse MMP-2 Substrate Degradome, Mol Cell Proteomics., 6, 611, 10.1074/mcp.M600341-MCP200 · DOI · Paper page
- Rowe, 2004, MEPE has the properties of an osteoblastic phosphatonin and minhibin, Bone., 34, 303, 10.1016/j.bone.2003.10.005 · DOI · Paper page
- Rowe, 2000, MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia, Genomics., 67, 54, 10.1006/geno.2000.6235 · DOI · Paper page
- Fisher, 2003, Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins, Connect Tissue Res., 44, 33, 10.1080/03008200390152061 · DOI · Paper page
- Liu, 2007, Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity, J Endocrinol., 192, 261, 10.1677/joe.1.07059 · DOI
- Rowe, 2006, Correction of the mineralization defect in Hyp mice treated with protease inhibitors CA074 and pepstatin, Bone., 39, 773, 10.1016/j.bone.2006.04.012 · DOI
- Bresler, 2004, Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets, J Endocrinol., 183, R1, 10.1677/joe.1.05989 · DOI
- Bai, 2002, Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression, Mol Endocrinol., 16, 2913, 10.1210/me.2002-0113 · DOI
- Martin, 2008, Degradation of MEPE, DMP1, and Release of SIBLING ASARM-Peptides (Minhibins): ASARM-Peptide(s) Are Directly Responsible for Defective Mineralization in HYP, Endocrinology., 149, 1757, 10.1210/en.2007-1205 · DOI · Paper page
- Boileau, 2001, Characterization of PHEX endopeptidase catalytic activity: identification of parathyroid-hormone-related peptide 107–139 as a substrate and osteocalcin, PPi and phosphate as inhibitors, Biochem J., 355, 707, 10.1042/bj3550707 · DOI
- Wang, 1999, Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential, J Bone Miner Res., 14, 893, 10.1359/jbmr.1999.14.6.893 · DOI · Paper page
- Sudo, 1983, In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria, J Cell Biol., 96, 191, 10.1083/jcb.96.1.191 · DOI · Paper page
- Denizot, 1986, Rapid colorimetric assay for cell growth and survival: Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability, Journal of Immunological Methods., 89, 271, 10.1016/0022-1759(86)90368-6 · DOI · Paper page
- Tullberg-Reinert, 1999, In situ measurement of collagen synthesis by human bone cells with a sirius red-based colorimetric microassay: effects of transforming growth factor β2 and ascorbic acid 2-phosphate, Histochem Cell Biol., 112, 271, 10.1007/s004180050447 · DOI · Paper page
- Masica, 2008, Solution- and adsorbed-state structural ensembles predicted for the statherin-hydroxyapatite system, Submitted.
- Makrodimitris, 2007, Structure Prediction of Protein-Solid Surface Interactions Reveals a Molecular Recognition Motif of Statherin for Hydroxyapatite, J Am Chem Soc., 129, 13713, 10.1021/ja074602v · DOI
- Pampena, 2004, Inhibition of hydroxyapatite formation by osteopontin phosphopeptides, Biochem J., 378, 1083, 10.1042/bj20031150 · DOI
- Hunter, 1994, Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation, Biochem J., 300, 723, 10.1042/bj3000723 · DOI · Paper page
- Hoyer, 2001, Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals, Kidney Int., 60, 77, 10.1046/j.1523-1755.2001.00772.x · DOI
- Grohe, 2007, Control of calcium oxalate crystal growth by face-specific adsorption of an osteopontin phosphopeptide, J Am Chem Soc., 129, 14946, 10.1021/ja0745613 · DOI
- Wang, 2008, Phosphorylation of Osteopontin Is Required for Inhibition of Calcium Oxalate Crystallization, The Journal of Physical Chemistry B., 112, 9151, 10.1021/jp804282u · doi:10.1021/jp804282u
- Gowen, 2003, Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass, J Biol Chem., 278, 1998, 10.1074/jbc.M203250200 · DOI · Paper page
- Hunter, 1996, Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins, Biochem J., 317, 59, 10.1042/bj3170059 · DOI · Paper page
- Goldberg, 1995, The inhibitory activity of osteopontin on hydroxyapatite formation in vitro, Ann NY Acad Sci., 760, 305, 10.1111/j.1749-6632.1995.tb44642.x · DOI
- Boskey, 1993, Osteopontin-hydroxyapatite interactions in vitro: inhibition of hydroxyapatite formation and growth in a gelatin-gel, Bone Miner., 22, 147, 10.1016/S0169-6009(08)80225-5 · DOI · Paper page
- Sorensen, 1995, Posttranslational modifications of bovine osteopontin: identification of twenty-eight phosphorylation and three O-glycosylation sites, Protein Sci., 4, 2040, 10.1002/pro.5560041009 · DOI · Paper page
- Lasa, 1997, Phosphorylation of osteopontin by Golgi apparatus casein kinase, Biochem Biophys Res Commun., 240, 602, 10.1006/bbrc.1997.7702 · DOI
- Lasa-Benito, 1996, Golgi apparatus mammary gland casein kinase: monitoring by a specific peptide substrate and definition of specificity determinants, FEBS Lett., 382, 149, 10.1016/0014-5793(96)00136-6 · DOI
- Meggio, 2003, One-thousand-and-one substrates of protein kinase CK2?, FASEB J., 17, 349, 10.1096/fj.02-0473rev · DOI · Paper page
- Addison, 2007, Pyrophosphate Inhibits Mineralization of Osteoblast Cultures by Binding to Mineral, Up-regulating Osteopontin, and Inhibiting Alkaline Phosphatase Activity, J. Biol. Chem., 282, 15872, 10.1074/jbc.M701116200 · DOI · Paper page
- Jono, 2000, Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification, J Biol Chem., 275, 20197, 10.1074/jbc.M909174199 · DOI · Paper page
- Hunter, 2008, Role of Phosphate Groups in Inhibition of Calcium Oxalate Crystal Growth by Osteopontin, Cells Tissues Organs.
- Kasugai, 1991, Differential regulation of the 55 and 44 kDa forms of secreted phosphoprotein 1 (SPP-1, osteopontin) in normal and transformed rat bone cells by osteotropic hormones, growth factors and a tumor promoter, Bone Miner., 13, 235, 10.1016/0169-6009(91)90071-7 · DOI
- Fisher, 2001, Flexible Structures of SIBLING Proteins, Bone Sialoprotein, and Osteopontin, Biochemical and Biophysical Research Communications., 280, 460, 10.1006/bbrc.2000.4146 · DOI · Paper page
- Goobes, 2006, Folding of the C-terminal bacterial binding domain in statherin upon adsorption onto hydroxyapatite crystals, Proc Natl Acad Sci USA., 103, 16083, 10.1073/pnas.0607193103 · DOI
- Guo, 2002, Inhibition of MEPE cleavage by PHEX, Biochemical and Biophysical Research Communications., 297, 38, 10.1016/S0006-291X(02)02125-3 · DOI
- Rowe, 2005, Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP), Bone., 36, 33, 10.1016/j.bone.2004.09.015 · DOI · Paper page
- Oefner, 2000, Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon, J Mol Biol., 296, 341, 10.1006/jmbi.1999.3492 · DOI · Paper page
Cited by
Osteocytes: master orchestrators of bone
Schaffler, M. B., Cheung, W.-Y., Majeska, R., & Kennedy, O. (2014) · Calcified Tissue International · doi:10.1007/s00223-013-9790-y · Cited by 514
Bone Quality: The Determinants of Bone Strength and Fragility
Fonseca, H., Moreira-Gonçalves, D., Coriolano, H.-J. A., & Duarte, J. A. (2014) · Sports Medicine · doi:10.1007/s40279-013-0100-7 · Cited by 429
Alkaline Phosphatase and Hypophosphatasia
Millán, J. L., & Whyte, M. P. (2016) · Calcified Tissue International · doi:10.1007/s00223-015-0079-1 · Cited by 397
Lieben, L., Masuyama, R., Torrekens, S., Van Looveren, R., Schrooten, J., Baatsen, P., Lafage-Proust, M.-H., Dresselaers, T., Feng, J. Q., Bonewald, L. F., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45890 · Cited by 369
Therapeutic management of hypophosphatemic rickets from infancy to adulthood
Linglart, A., Biosse-Duplan, M., Briot, K., Chaussain, C., Esterle, L., Guillaume-Czitrom, S., Kamenicky, P., Nevoux, J., Prié, D., Rothenbuhler, A., et al. (2014) · Endocrine Connections · doi:10.1530/ec-13-0103 · Cited by 331
FGF23 and its role in X-linked hypophosphatemia-related morbidity
Beck-Nielsen, S. S., Mughal, Z., Haffner, D., Nilsson, O., Levtchenko, E., Ariceta, G., de Lucas Collantes, C., Schnabel, D., Jandhyala, R., & Mäkitie, O. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1014-8 · Cited by 278
Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway
Rowe, P. S. N. (2012) · Critical Reviews™ in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v22.i1.50 · Cited by 173
Metadata
- Authors
- Addison, W. N., Masica, D. L., Gray, J. J., & McKee, M. D.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-04-01
- Volume
- 25
- Issue
- 4
- Pages
- 695-705
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2094273009
- Cited by
- 229
- References
- 2
- FWCI
- 8.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.